Disaster Information Management Research Center | NLM

Disaster Information Management Research Center | NLM

Fact Sheet for Healthcare Providers: SGTi-flex COVID-19 IgG

09/03/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 9/3/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the SGTi-flex COVID-19 IgG. The SGTi-flex COVID-19 IgG is authorized for the detection of IgG antibodies to SARS-CoV-2 in human serum, venous whole blood (sodium heparin, lithium heparin, sodium citrate and tripotassium EDTA), andplasma (sodium heparin, lithium heparin, sodium citrate and tripotassium EDTA). (PDF)